Another Benefit of GLP-1s: Lower Risk of Cirrhosis Among Those With Diabetes and MASLD
The advantage of the glucago-like peptide 1s did not include people who had already developed cirrhosis,
It seems like a day doesn’t go by without another positive finding for the glucagon-like peptide 1 (GLP-1) receptoragonist drugs, a class that includes Ozempic (semaglutide) and Wegovy (semaglutide when it is sold for weight loss).
Today is no exception. According to a findings from a large, retrospective reported today in JAMA Internal Medicine, GLP-1s reduced risk of developing cirrhosis among patients with diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) relative to those using dipeptidyl peptidase 4 inhibitors (DPP-4is) by 14%. The DPP-4is include DPP-4is Januvia (sitagliptin) and Tradjenta (linagliptin).
The GLP-1s were associated with a protective effect for a number of secondary outcomes, including a composite outcome of cirrhosis outcome (22% less risk compared to DPP-4i use) and mortality (an 11% difference).
The difference between the GLP-1s and the DPP-4is emerged between 18 to 24 months after patients started taking the medications and increased as time went on, according to the research findings.
But the advantage of the GLP-1s over the DPP-4is did not extend to those who already had cirrhosis. Corresponding author Fasiha Kanwal, M.D., M.S.H.S., of Baylor College of Medicine and his colleagues did not find lower rates of more serious liver disease or hepatocellular cancer among GLP-1s users compared to DPP-4is users among those had cirrhosis when they started taking the medications.
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Careful Consideration Needed for Management of Acquired (Autoimmune) Hemophilia
May 22nd 2025Patients diagnosed with acquired (autoimmune) hemophilia, a serious and rare bleeding disorder, have high rates of hospital readmissions because of infections and bleeding, as well as high death rates especially among older patients.
Read More
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Value-Based Care Adoption is Slow Across Global Health Systems
May 20th 2025Value-based healthcare programs are mostly used in rich countries and usually only in small parts of health systems. According to a study published in JAMA Health Forum, these tools can be harder to implement because of system problems, not enough long-term information and lack of research in low-income countries.
Read More
